Evidence map›Paper›PMID 31038986›Full record

ArticleAmerican journal of respiratory and critical care medicine2019

Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction. Where to Draw the Line.

Marc A Simon, Bradley A Maron

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of respiratory and critical care medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Marc A Simon1Department of Medicine.
Bradley A Maron4Department of MedicineBrigham and Women's Hospital and Harvard Medical SchoolBoston, Massachusettsand.

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Vascular Subphenotypes of Lung DiseaseP01HL103455 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GLADWIN, MARK T · 2011 to 2020
$26.1M
Targeting FAK-NEDD9 protein-protein interaction to prevent focal adhesion assembly and vascular proliferation in pulmonary arterial hypertensionR01HL139613 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI Sirano Dhe-Paganon, Bradley Maron · 2018 to 2026
$4.1M
Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure with Preserved Ejection FractionR01AG058659 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SIMON, MARC A · 2018 to 2022
$3.2M
Fibrosome regulation by aldosterone in pulmonary vascular diseaseR56HL131787 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MARON, BRADLEY · 2017 to 2017
$445k
Network medicine, risk stratification, and pulmonary hypertensionR21HL145420 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MARON, BRADLEY · 2019 to 2020
$287k
NCATS NIH HHS UL1 TR000005NHLBI NIH HHS P01 HL103455NHLBI NIH HHS R01 HL139613NHLBI NIH HHS R21 HL145420NHLBI NIH HHS R56 HL131787NIA NIH HHS R01 AG058659
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Heart FailureHypertension, PulmonaryHumansStroke Volume

Identifiers

PMID31038986
PMCPMC6680312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.